Welcome to the ATTD 2023 Interactive Program

Session Description: Technologic advancements in glucose monitoring, insulin formulation, and insulin delivery have been essential to improving clinical outcomes for individuals with type 1 diabetes (T1D). However, the psychosocial burden of T1D can persist despite these technologies, and results observed in clinical trials have not necessarily translated to all patients in real-world practice. This educational non-CME symposium, chaired by Prof. Chantal Mathieu, will focus on successes and gaps with current T1D management and the potential for islet cell replacement to address the serious unmet need that remains in some patients despite diabetes technologies.

Dr. William Polonsky will describe the multidimensional burden of T1D, exploring if diabetes technologies can fully eliminate this burden. Dr. Richard Bergenstal will then report clinical trial and real-world evidence in T1D management, highlighting a patient population that experiences unfavorable outcomes despite technology utilization. Finally, Dr. Michael Rickels will summarize the field of islet cell therapy, providing an update on the most recent data for islet cell transplantation and possible future advances in the field. The session will close with a moderated Q&A with the panel.